­
­
­
­

Inventi Rapid - Pharm Tech

Articles

  • Inventi:ppt/25678/18
    FORMULATION AND EVALUATION OF SUBLINGUAL TABLETS OF CLOBAZAM
    Mayur Patel*, Mehul Vyas, Jagruti Desai, Biren Patel, M Rahil Bhura, Samir Shah

    The aim of present work was to formulate and evaluate sublingual tablets of clobazam for the management of epileptic attacks with quick onset of action particularly in children. It was prepared by direct compression method and with improved solubility of drug by solid dispersion technique. The purpose of present work was to formulate and evaluate sublingual tablets of clobazam with different concentration of superdisintegration. The present work was attempted to prepare solid dispersion by solvent evaporation method using different concentration of PVP K-30 polymer. Solid dispersion was evaluated and the results obtained with different concentration of PVP K-30 were compared. Preliminary batches of sublingual tablets were prepared by direct compression method using crospovidone, kyron T-314, croscarmellose sodium and sodium starch glycolate which were evaluated in order to select suitable superdisintegration for further studies. Nine batches were prepared as per 32 factorial designs, to study the combined effects of crospovidone and kyron T-314 on tablet. All tablets were evaluated for the parameters like weight variation, friability and thickness, wetting time, disintegration time, hardness, drug contents and % drug release. FT-IR and DSC studies showed that there was no interaction between drug and polymer. The results showed that PVP K-30 and drug (1:3) showed maximum drug solubility which was further utilized in formulation of sublingual tablets. In preliminary trials results it showed that kyron T-314 and crospovidone were found more effective as compared to sodium starch glycolate and croscarmellose sodium. Results of all nine batches shows that F9 batch was selected as optimised batch with lower disintegration time (17.66 sec), wetting time (10.66 sec) and higher % drug release (99.63%). The stability study of F9 was carried out for 1 month. The result showed that there is no significant change in tablet properties. The present approach of formulating sublingual tablets of clobazam has been achieved by F9 batch containing kyron T-314 (8 mg) and crospovidone (10 mg) seems to be promising formulation and prepared solid dispersion 1:3 (PVP K-30 and drug) gives improved solubility of clobazam.

    How to Cite this Article
    Mayur Patel, Mehul Vyas, Jagruti Desai et al. Formulation and Evaluation of Sublingual Tablets of Clobazam. Inventi Rapid: Pharm Tech, 2018(3):1-13, 2018.
    Download Full Text